Congratulations to Sven, who published an article in Bioorganic & Medicinal Chemistry Letters about the prospects of main protease inhibitors as antiviral agents to combat COVID-19. Our article is open access and available to everyone.
Small molecules inhibit flavivirus proteases in the active site
Check out our latest article published in ACS Medicinal Chemistry Letters in close collaboration with the Wolber and Rademann laboratories in Berlin. For the first time, we demonstrate that small molecules can target the active sites of Zika, West Nile and dengue virus proteases with extraordinarily high affinities.
Inhibitors of the Zika virus protease NS2B-NS3
Congratulations to Saan, who published an article in Bioorganic & Medicinal Chemistry Letters about the latest prospects of protease inhibitors as antiviral agents to combat infections with the Zika virus. Our article is featured on the cover of the latest issue.
Biocompatible Peptide Macrocyclisation Generates Stable Protease Inhibitors
Check out our latest research article published in Organic Letters about a novel strategy to spontaneously cyclise peptides under physiological conditions. A substrate peptide of the Zika virus protease cyclised in this way produced an inhibitor of remarkable affinity and stability.
Proteases from dengue, West Nile and Zika viruses as drug targets
Check out our latest review about the potential of protease inhibitors to combat diseases associated with dengue, West Nile and Zika virus infections published in Biophysical Reviews.
Featured Letter in ACS Medicinal Chemistry Letters
Our latest paper on macrocyclic peptide inhibitors of the Zika virus protease has been published as a Featured Letter in ACS Medicinal Chemistry Letters and invited to contribute the cover for the February issue.
